Related Experiment Video
Updated: May 17, 2026
In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
Published on: May 4, 2017
[Immunologic changes in diffuse large B-cell lymphomas after rituximab-CHOP treatment: own data and review of the
Zsófia Simon1, Arpád Illés, Zsófia Miltényi
1Debreceni Egyetem, Orvos- és Egészségtudományi Centrum Belgyógyászati Intézet, Hematológia Tanszék Debrecen Nagyerdei krt. 98. 4032. zsocogo@gmail.com
Introduction:
Rituximab treatment may induce a long-term B-cell depletion, which can be accompanied with an increased infection risk.
Aims:
To examine the changes of the white blood cell, CD19+ B-cell and CD4+ T-cell counts and the levels of immunoglobulin G, A, M after rituximab containing chemotherapy and to explore the infectious complications in our patients and review of the literature.
Patients And Methods:
Thirty-five diffuse large B-cell lymphoma patients were examined, who were treated with rituximab-cyclophosphamide-vincristine-doxoribicine-prednisolone (R-CHOP). The B- and T-cell populations were analyzed with flow-cytometry while the immunoglobulin levels were measured by nephelometry.
Results:
CD19+ B-lymphocytes were undetectable after the treatment and their count only increased from the post-therapeutic 12th month. Infection did not occur in this group of patients.
Conclusions:
Rituximab induced B-cell depletion was appreciable also in this group of patients, while serious or unexpected infection did not occur. Increased infectious risk primarily can be observed after long-term, maintenance rituximab treatment.
